Dipanjan Pan RNA Disease Diagnostics (RNADD) appointed its chief scientific advisor, Prof. Dipanjan Pan, Ph.D., and company president, John Erickson, Jr., to the board to further position RNADD to execute the next...
RNA Disease Diagnostics (RNADD) secured an exclusive global license to a rapid ribonucleic acid-based molecular lateral flow assay (LFA) technology jointly owned by the University of Maryland, Baltimore (UMB) and the...
Michael Farber Closely-held RNA Disease Diagnostics appointed board-certified internist and professional sports physician, Michael Farber, M.D., to its advisory board. Dr. Farber is the medical director of executive...
Closely-held RNA Disease Diagnostics appointed Robert Ganz, a healthcare veteran with more than 40 years of executive experience in venture-backed startups and international healthcare companies, to the board. Mr. Ganz...
The FDA registered the laboratory of Dipanjan Pan, Ph.D., at the University of Maryland School of Medicine, as an approved laboratory development site for RNA Disease Diagnostics’ (RNADD) Antisense COVID-19 molecular...
John Erickson Jr. RNA Disease Diagnostics (RNADD) appointed John Erickson, Jr. to the newly created position of president to lead day-to-day operations. He will report directly to company co-founder and executive...
Closely-held RNA Disease Diagnostics held an inaugural joint meeting of its board of directors and advisory board, which will work alongside the leadership team to advance the company’s...
RNA Disease Diagnostics’ stepwise protocol for an RNA-extraction-free nano-amplified colorimetric test for COVID-19 was published in Nature Protocols. The test uses a unique dual-pronged molecular...